PERRIGO Co plc (PRGO)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$357.2M
Cash & Equivalents
$113.6M
Quarterly Burn Rate
9 mo
Est. Cash Runway
$1,414M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
CLINDAMYCIN PHOSPHATE
CLINDETS |
NDA | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-31 | Phase3 Readout | — |
| 2027-03-01 | Phase3 Readout | — |
Active Clinical Trials (16)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT00602641 | Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma | PHASE3 | Active Not Recruiting | 306 |
| NCT03959085 | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute L... | PHASE3 | Recruiting | 5,951 |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | PHASE3 | Recruiting | 1,875 |
| NCT03914625 | A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Le... | PHASE3 | Active Not Recruiting | 6,720 |
| NCT02166463 | Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, ... | PHASE3 | Active Not Recruiting | 600 |
| NCT04799275 | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diff... | PHASE3 | Active Not Recruiting | 422 |
| NCT03984448 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | PHASE3 | Active Not Recruiting | 363 |
| NCT04759586 | Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lympho... | PHASE3 | Active Not Recruiting | 244 |
| NCT02003222 | Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Linea... | PHASE3 | Active Not Recruiting | 488 |
| NCT06124157 | A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adole... | PHASE2 | Recruiting | 222 |
| NCT06317662 | Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual C... | PHASE2 | Recruiting | 153 |
| NCT02522715 | Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer | PHASE2 | Active Not Recruiting | 37 |
| NCT05761171 | A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia | PHASE2 | Active Not Recruiting | 78 |
| NCT00972478 | Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or St... | PHASE2 | Active Not Recruiting | 83 |
| NCT03269669 | Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or... | PHASE2 | Active Not Recruiting | 73 |
| NCT01856192 | Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-I... | PHASE2 | Active Not Recruiting | 349 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.